The Initial Public Offering (IPO) of Ahmedabad-based Concord Biotech Limited, a biotechnology company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022 was oversubscribed by 24.86 times on the last day of subscription.
The issue received bids of 36,42,82,880 shares against the offered 1,46,50,957 equity shares, at a price band of ₹705-741, according to the data available on the stock exchanges.
Qualified Institutional Buyer Portion was the most subscribed with 67.67 times; followed by Employee Portion was subscribed 24.47 times. Non-Institutional Investors Portion was subscribed 16.99 times, whereas, Retail Portion was subscribed 3.78 times. A Discount of Rs 70/- per equity share is being offered to Eligible Employees bidding in the Employee Reservation Portion.
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited and Jefferies India Private Limited are the book running lead managers and Link Intime India Private Limited is the registrar for the issue.
Concord Biotech
Concord Biotech is country-based. It is a global supplier of bio-pharmaceutical APIs and formulations, serving more than 70 countries, including regulated markets like the United States, Europe, Japan, and India. According to the Frost & Sullivan Report, the company holds an impressive market share of over 20% by volume in 2022 for fermentation-based API products, including mupirocin, sirolimus, tacrolimus, mycophenolate sodium, and cyclosporine. Its substantial success can be attributed to its total installed fermentation capacity of 1,250 m3 as of March 31, 2023.
Furthermore, Concord Biotech expanded its reach by venturing into the formulation business in India and emerging markets such as Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore, and Paraguay. The company specializes in manufacturing bio-pharmaceutical APIs through fermentation and semi-synthetic processes, with a focus on therapeutic areas such as immunosuppressants, oncology, and anti-infectives. Additionally, they provide formulations for critical care in areas like immunosuppressants, nephrology drugs, and anti-infective drugs.
